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Probe-basedConfocalLaserEndomicroscopy(pCLE)isanovelimagingtechniqueforgastrointestinalendoscopyprovidinginvivo
microscopy at subcellular resolution. It oﬀers the possibility to analyze neoangiogenesis and vessel density in vivo. Angiogenetic
switch is essential in cancer progression. Aim of the paper was to review the use of this imaging tool to analyze colorectal and
gastric cancers vascularization in vivo. The aim is to provide the possibility of combining diagnostic evidences with vascularization
and molecular proﬁle to evaluate the eﬃcacy of an antiangiogenic treatment in association with conventional therapy. pCLE can
be considered a revolutionary method for real-time assessment of changes in vascularization pattern in this tumors and it may
open the possibility to address the use of anti-angiogenic therapy in order to improve the outcome of the treatment.
1.Introduction
In recent years, endoscopic image quality has been highly
improved thanks to very technologically advanced devices.
One of these new gastrointestinal endoscopy methods is the
confocal laser endomicroscopy (CLE) which has allowed for
a confocal scanning microscope to be integrated into a con-
ventional ﬂexible endoscope. Potential applications include
detection of neoplasia with targeting of biopsies, and the de-
tection of inﬂammatory bowel disease, celiac sprue, and mi-
croscopic colitis [1]. CLE provides in vivo microscopy at sub-
cellularresolution:imagingofthemucosallayeratresolution
at approximately 1 micron and visualization of the cellular
and subcellular structures as well as capillaries and single red
blood cells are peculiar characteristics of this novel gastroin-
testinal endoscopy method. We experienced with the probe-
based confocal endomicroscopy system (pCLE, Cellvizio,
Mauna Kea Technology, Paris, France), in combination with
videomosaicing which allows the reconstitution of panora-
mas of the tissues with the alignment of the input frames.
We aimed therefore to use this new promising imaging tool
to analyze the angiogenic process in colo-rectal and gastric
cancer patients. This method discloses the possibility of a
translational approach combining the confocal imaging not
only with the diagnosis in vivo and the speciﬁc molecular
proﬁle of the patient, but also with the targeted antiangio-
genic treatment.
2. Endomicroscopy andTumors
The potential role of CLE has been explored in diﬀerent
pathologic conditions of the gastrointestinal (GI) tract, the
possibilityofdiagnosingpremalignantandmalignantlesions
of the GI tract being particularly important considering the
prognostic implications. GI cancers represent a major cause
of morbidity and mortality, with incomplete response to
chemotherapy and poor prognosis in the advanced stages of
the disease. Recently, CLE has been successfully applied in2 Gastroenterology Research and Practice
studies dedicated in particular to neoplastic Barrett’s esoph-
agus, and gastric and colorectal neoplasia. Since accurate
diagnosis and staging are essential for therapeutic planning,
CLE holds the potential for a strong impact in the screening
and/or surveillance of GI tumors [2, 3]. CLE has been used
in a pilot study also for detection of biliary malignancy [4].
All the studies performed revealed the clinical usefulness and
predictive power for the high-resolution probe-based CLE
for in vivo diagnosis of GI neoplasia and related precursor
lesions during colonscopy. Based on characteristic morpho-
logical changes or due to characteristic single cells like globet
cellsinBarrett’sesophagus,thepromisingtechnologyofCLE
enables already in vivo diagnosis of pathological mucosal
conditions. However, confocal imaging holds the potential
to go far beyond: the possibility to analyze the morphology
and density of the blood vessels present on the surface of
the tumors could also provide vital information for a more
appropriate diagnosis and for a putative employment anti-
angiogenic drugs during the treatment.
3. AngiogenesisMarkers
The development of new blood vessels from the preexisting
vasculature (angiogenesis) is an indispensable event both in
normal and pathological conditions, such as cancer growth
and development. Tumors will not grow beyond 1-2mm
unless the angiogenic switch is turned on [5], thus the for-
mation of novel blood vessels is regarded as one of the most
important events occurring in the neoplastic process [6]. In
fact, the development of new vessels supplies the growing
tumor with nutrients and oxygen, disposing metabolites and
releasing growth factors that promote tumor cell prolifer-
ation [7]. Indeed tumors promote angiogenesis by secreting
growth factors such as vascular endothelial growth factor
(VEGF), hepatocytes growth factor, and platelet-derived
growth factor that stimulate endothelial migration and pro-
liferation [7–9]. The binding of VEGF to VEGFR triggers an
intracellular signaling that is mainly mediated by MAPK and
PI3K/Akt/mTOR pathways. This results in the expression of
HIF-1a and induction of PDGF, FGF, G-CSF, TGFβ,a n da n -
giopoietins, thus enhancing angiogenesis [10]. Angiogenesis
is also indispensable to the metastatic process by providing
large numbers of leaking blood vessels for vascular invasion
[7]. To early detect and assess the extent of the intratumor-
al angiogenesis is thus crucial for a personalized and prompt
antiangiogenic therapy. Besides the commonly used panen-
dothelialmarkerssuchasCD31,CD34,FactorVIII,endoglin
(CD105) has been proposed as a marker of tumor angiogen-
esis since the endoglin antibody binds preferentially to the
activatedendothelial cellsthatparticipate neovascularization
[11, 12]. Endoglin is a receptor for the TGF-β1m o l e c u l e
and was indeed found to be upregulated during neoangiog-
enesis [13]. Among the molecules speciﬁcally located along
the blood vessels, MULTIMERIN2 (a.k.a. EndoGlyx-1)
can be considered a good marker for the blood vessels.
MULTIMERIN2 (MMRN2) belongs to the (EMI Domain
ENdowed) EDEN protein family [14]. The protein was dis-
covered during the search of novel markers of the vascular
endothelium [15]. MMRN2 is in association with a high-
molecular weight glycoprotein complex. Two subunits of this
complex match the MMRN2 sequence and are likely the
result of to posttranslational modiﬁcations. The other two
subunits have not yet been identiﬁed [16]. MMRN2 can be
considered a panendothelial marker being expressed both
in normal and tumoral vasculature including hot spots of
neovascularisation in some tumors [15–18]. The molecule
wasshowntobespeciﬁcallydepositedalongthebloodvessels
in tight juxtaposition with endothelial cells and to be also
present in the luminal side of the vessels [16]. Prior to our
studies, its function though has remained obscure. Recent
data collected in our laboratory [19] indicate that this mole-
cule plays an important role in the regulation of endothelial
cellfunction,tumorangiogenesis,andvesselhomeostasis.To
carry out these studies, we have developed both antihuman
and antimouse antibodies against this molecule which were
found to detect blood vessels in many tissue and tumor
sections as well as the anti-CD31 antibody [19]. The use of
this antibody was found to be suitable for the detection of
blood vessels both in colorectal and gastric cancer sections
as indicated by our results. Interestingly, MMRN2 was also
demonstratedtoplayanimportantroleinvesselsmaturation
(in terms of pericyte coverage) and to regulate also endo-
thelial cell permeability [19]. Thus this molecule may not
onlybeameremarkerofbloodvesselsbutalsobeimportant,
depending on its expression, in predicting the vessel func-
tionality. Indeed, the combination of the MMRN2 staining
with the pCLE analysis could provide a more reliable evalua-
tion of the “angiogenetic status” of the patients.
4. Endomicroscopy andAngiogenesis
High-resolution confocal imaging is achieved by using an
exogenous ﬂuorescence technique. Fluorescein is intrave-
nously administered for speciﬁc in vivo imaging of human
colorectal neoplasia and its use also allows the analysis of the
vascular structure, morphology (irregular vessels) and leak-
iness (ﬂuorescein outﬂow). Studies are currently underway
to apply this new imaging tool for objective evaluation of the
microvesseldensityindiﬀerentstagesoftheneoplasticdevel-
opment and in conjunction with antiangiogenetic therapy.
Preliminary data on the microvessel density for biliary can-
cers at the liver hilum [20, 21], for Barrett’s esophagus [22],
and for GI tumors [23, 24], are currently available.
Endoscopic imaging and monitoring of angiogenesis
havethepotentialtobevaluablebiomarkersinpreneoplastic,
premalignant,andcancerstageinGIlesions.The“endoscop-
ic angiogenesis” analysis on gastric and colo-rectal cancers
was performed on the patients listed in Table 1.W eev a l u a t ed
pCLE images from 25 sequences/biopsy sites and compared
withthehistologicaldata.Thevasculararchitectureincancer
patients was abnormal (enlarged, tortuous microvessels with
altered blood ﬂow). The morphological pattern of neoan-
giogenesis was in accordance with the histology and im-
munohistochemical analysis, allowing us to develop an ar-
bitrary “angiogenesis” scale whose criteria are reported in
Table 2. The Cannizzaro-Spessotto scale evaluates the extent
of intratumoral angiogenesis based on the increase of the
number of vessels, the presence of tortuous and large vessels,Gastroenterology Research and Practice 3
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Figure 1: Representative pictures of the images obtained during pCLE endoscopy where the presence of tortuouse large blood vessels with
defective ﬂux and leakage are indicated by the arrows.
Table 1: Patients enrolled for pCLE analysis.
Patient Age F/M Diagnosis Grade/Staging
(EUS)
1D M 6 4 M A d e n o m a
2 ML 62 F Rectal neoplasia T3N+
3 GG 60 M Gastric neoplasia T1N0
4 CG 51 F Rectal neoplasia T3N+
5 ZI 71 M Rectal neoplasia T3M+
6C P 6 3 F Rectal neoplasia
(stenosis)
7 GM 77 F Rectal neoplasia T3N0
8 SS 38 M Rectal neoplasia T3N + M?
9 TB 68 M Rectal neoplasia T3Nx
10TC 54 M Rectal neoplasia T3N+
11FL 66 F Gastric neoplasia T3N+
ﬂuorescein leakage, and defective ﬂux (Figure 1). Even if
preliminary, these data (reported in Table 3) suggest that the
application of Cannizzaro-Spessotto scale could be helpful
Table 2: Calculation of Cannizzaro-Spessotto scale.
Criterion
Score
No Yes
Tortuous vessels 0 1
Large vessels 0 1
Leakage 0 1
Defective ﬂux 0 1
The patient’ s angiogenesis index is obtained by summing the scores of the
single items.
in predicting the response to anti-angiogenic therapy and
possible chemoresistance of a tumor during treatment and if
the treatment received has been insuﬃcient to avoid surgery.
F u r t h e rd a t ao nag r e a t e rn u m b e ro ft u m o r sa td i ﬀerent sta-
ges are needed to improve the diagnostic accuracy and to
guide and predict the more appropriate individualized strat-
egies for the treatment.4 Gastroenterology Research and Practice
Table 3: “Angiogenetic status” of the patients.
Patient “Angiogenesis” index (Cannizzaro-Spessotto scale)
1D M 0
2M L 3
3G G 2
4C G 2
5 ZI Not applicable (stenosis)
6 CP Not applicable (stenosis)
7G M 4
8S S 3
9T B 2
10 TC 2
11 FL 3
5. Conclusions andPerspectives
The use of pCLE allowed the in vivo assessment of the mor-
phological alterations and the abnormal microvasculature
of the cancer mucosa and the results correlated with the
traditional conventional approach. pCLE can be considered
a crucial and revolutionary method for real-time analysis of
the vascularization pattern in colo-rectal and gastric cancer.
These preliminary results indicate that pCLE in combination
with immunological staining (CD31 and MMRN2) hold the
potential for a signiﬁcant impact both on basic research and
clinical practice, suggesting a substantial possibility for a
translational study.
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